Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prednisolone plus SPI-62 versus prednisolone plus placebo in polymyalgia rheumatica
2022-000299-20Phase 2Active
- Sponsor
- Sparrow Pharmaceuticals
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in polymyalgia rheumatica (PMR) comparing SPI-62 + prednisolone with Placebo + prednisolone (2 arms). Primary endpoints: Fibrinogen, Erythrocyte sedimentation rate and 1 more. Started Apr 2022; status: active.
02
Drugs
clofutriben
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on 2022-000299-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000299-20.